An increased cancer-related inflammation response inhibits the generate of erythropoietin, reduces iron release from reticuloendothelial macrophages, and shortens red blood cell survival through relevant inflammatory markers, which results in elevated RDW; however, the potential mechanism has not been demonstrated clearly [20]. This evidence concerns the gene EPO and cancer.